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Introduction
Chronic myelomonocytic leukemia (CMML) is classified
by the WHO as a clonal hematopoietic malignancy character-
ized by features of both a myeloproliferative neoplasm and a
myelodysplastic syndrome.1 CMML accounts for 10% of all
cases of myelodysplastic syndromes;2,3 affected patients are
diagnosed at a median age of 65-75 years, and there is a 2 to
1 male predominance.3 The most common symptoms of
CMML are a reflection of the underlying cytopenia, hyper-
catabolic syndrome, splenomegaly, or organ infiltration of
monocytes.  The disease presents with variable clinical phe-
notypes, the prognosis is generally poor, and effective thera-
pies are limited.2 In recent years, array and sequencing tech-
nologies have provided new insights into the molecular
pathogenesis of CMML.2 Molecular discoveries, however,
have not yet been translated into changes in disease manage-
ment. Therefore, therapy for CMML remains a challenge. For
this reason, the Italian Society of Hematology (SIE) and affil-
iated Societies (the Italian Society of Experimental
Hematology, SIES, and the Italian Group for Bone Marrow
Transplantation, GITMO) decided to review recent data
regarding diagnostic criteria, evaluation needs at diagnosis,
assessment of prognostic risk, and determinants of therapeu-
tic intervention, in order to produce recommendations aimed
at helping to optimize and standardize CMML clinical man-
agement.
Methods
An expert panel of 8 hematologists with a long experience and sci-
entific interest in CMML was selected. During an initial meeting on
December 2011, the areas of major concern in the management of
CMML were identified. Clinical key-questions were generated and
rank-ordered using the criterion of clinical relevance (Table 1).
Each panelist drafted statements that addressed the key questions,
and the remaining panelists scored their agreement with those state-
ments providing suggestions for re-phrasing. To exploit this phase of
the process, the Delphi questionnaire method was used.4 Finally, the
panel met three times in Bologna, Italy, for consensus conferences.
The nominal group technique5 was used according to which partici-
pants were first asked to comment in round-robin fashion on their
preliminary votes and then to propose a new vote.  
Results
Patient evaluation at diagnosis
The diagnosis of CMML relies largely on findings of bone
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With the aim of reviewing critical concepts and producing recommendations for the management of chronic
myelomonocytic leukemia, key questions were selected according to the criterion of clinical relevance.
Recommendations were produced using a Delphi process and four consensus conferences involving a panel of
experts appointed by the Italian Society of Hematology and affiliated societies.  This report presents the final state-
ments and recommendations, covering patient evaluation at diagnosis, diagnostic criteria, risk classification, first-line
therapy, monitoring, second-line therapy and allogeneic stem cell transplantation. For the first-line therapy, the panel
recommended that patients with myelodysplastic-type chronic myelomonocytic leukemia and less than 10% blasts
in bone marrow should be managed with supportive therapy aimed at correcting cytopenias. In patients with
myelodysplastic-type chronic myelomonocytic leukemia with a high number of blasts in bone marrow (≥10%), sup-
portive therapy should be integrated with the use of 5-azacytidine. Patients with myeloproliferative-type chronic
myelomonocytic leukemia with a low number of blasts (<10%) should be treated with cytoreductive therapy.
Hydroxyurea is the drug of choice to control cell proliferation and to reduce organomegaly. Patients with myelopro-
liferative-type chronic myelomonocytic leukemia, and a high number of blasts should receive polychemotherapy.
Both in myelodysplastic-type and myeloproliferative-type chronic myelomonocytic leukemia, allogeneic stem cell
transplantation should be offered within clinical trials in selected patients.
ABSTRACT
marrow (BM) morphological dysplasia or clonal genetic
abnormalities in patients with persistent peripheral blood
monocytosis. Conventional cytogenetic analysis can allow
clonal abnormalities to be indentifed, even if most patients
with CMML exhibit a normal karyotype.6 The most fre-
quent abnormalities involve chromosome 7, mostly con-
sisting of monosomy, trisomy 8, and a complex karyotype
involving 3 or more abnormalities.7
Several molecular gene mutations have been found in
CMML.8-10 These mutations affect different cellular targets
and processes, like RUNX19,11,12 (transcription regulation),
isocitrate dehydrogenases IDH1/IDH213 (metabolism),
KRAS, NRAS, CBL, and JAK29,14-17 (tyrosine-signaling path-
ways), TET2, DNMT3A, ASXL1, UTX, EZH28,18-21 (epige-
netic regulatory mechanism), and SRSF222 (splicing regula-
tion). Mutations involving the NRAS, KRAS, TET2, CBL
and SRSF2 genes, and JAK2 V617F mutations are the most
frequently reported.22 A comprehensive mutation analysis
revealed that 93% of all CMML patients carried at least
one somatic mutation in 9 recurrently mutated genes.22
Flow cytometry immunophenotyping may detect aber-
rancies in the monocytic lineage, including abnormal
CD11b/HLA-DR, CD36/CD14, abnormal intensity of
CD13, CD14, CD16, CD33, CD36, CD64, expression of
CD34 and lineage infidelity markers, and overexpression
of CD56.23-25 None of these aberrancies are specific for
CMML.
Recommendations
The diagnostic workup of a suspected CMML should
include: patient’s history aimed at excluding reactive
causes of monocytosis (in particular, infectious diseases
and solid tumors); physical examination (in particular,
assessment of spleen size and search for cutaneous
lesions); complete blood count and peripheral blood
smear examination with differential leukocyte count;
bone marrow aspiration and biopsy; conventional cyto-
genetic analysis; molecular assays to exclude bcr/abl
fusion gene and rearrangement of PDGFRA and
PDGFRB; any investigation necessary to exclude infec-
tious diseases with monocytosis. A sample of bone mar-
row cells should be stored for possible further molecular
analysis in centers where a certified tissue bank is avail-
able.
Useful diagnostic information gained from peripheral
blood smear examination includes: monocyte count;
presence of dysgranulopoiesis; presence of promono-
cytes, blasts, and neutrophil precursors. Useful diagnos-
tic information from bone marrow aspiration is: pres-
ence of dysplasia in one or more myeloid lineages;
granu locytic hyperplasia; percentage of blasts, that
should include myeloblasts, monoblasts and promono-
cytes.
Staining of bone marrow biopsy sections should
include hematoxylin-eosin or equivalent, immunostain-
ing for CD34+ and monocytic cells (CD68R and CD163),
and Gomori's silver impregnation for fibrosis. Useful
diagnostic information from BM biopsy is: marrow cel-
lularity; dysplasia and hyperplasia of megakaryocyte
compartment; blast count; and bone marrow fibrosis.
Conventional cytogenetic analysis should allow
acquired clonal chromosomal abnormalities to be
detected and t(9;22) and t(5;12) translocations excluded
that are characteristic for chronic myeloid leukemia and
MDS/MPN with eosinophilia, respectively.
In patients with negative t(9;22), bcr/abl fusion gene
molecular assay should be performed to definitively
exclude chronic myeloid leukemia. In the case of
eosinophilia and  negative t(5;12), the PDGFRA and
PDGFRB rearrangement  molecular assay should be per-
formed in order to exclude MDS/MPN with eosinophil-
ia.
The panel agreed that validation of potential diagnos-
tic molecular biomarkers, like SRSF2, TET2, JAK2 or
RAS mutations, and a better knowledge of their speci-
ficity is needed before they can be indicated for routine
assessment in CMML patients at diagnosis.
Comprehensive diagnostic criteria 
Diagnostic criteria proposed by the FAB group in the
1980s included: blood monocytes > 1x109/L; bone marrow
blasts <20%, associated with dysplasia in erythroid, gran-
ulocytic, or megakaryocytic lineages; peripheral blasts <
5%; and absence of Auer rods in myeloid cells.26 Due to
the variability of this presentation, in 1994 the FAB group
distinguished “dysplastic” (MD-CMML) and “prolifera-
tive” (MP-CMML) variants, considering a white blood cell
(WBC) count of 13x109/L as a cut-off point.27 In most of
the studies investigating the prognostic significance of
such a subdivision,28-34 median survival of patients with the
MP-CMML turned out to be shorter than that of patients
with the MD-variant, even though the observed differ-
ences were hardly ever statistically significant. On the
contrary, the probability of transformation to acute
myeloid leukemia (AML) was generally similar between
the two subtypes of CMML. 
In 2001, the WHO classification definitively separated
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Table 1. The nine key questions selected by the panel and deemed to
be relevant for the management of CMML.
1. Patient evaluation at diagnosis
2. Comprehensive diagnostic criteria
3. Prognosis and risk classification
4. Determinants of therapeutic interventions, including 
investigations to be done before planning therapy
5. Response criteria
6. Goals of therapy
7. Monitoring patients not candidates for treatment
8. First-line therapy
9. Second-line therapy and stem cell transplantation
Table 2. WHO diagnostic criteria of chronic myelomonocytic leukemia.1
1. Persistent peripheral blood monocytosis (> 1×109/L); 
2. No Philadelphia chromosome or BCR-ABL1 fusion gene; 
3. No arrangement of PDGFRA or PDGFRB (these rearrangements
should be specifically excluded in cases with eosinophilia); 
4. Less than 20% blasts in the peripheral blood and the bone marrow 
(blasts includes myeloblasts, monoblasts, and promonocytes); 
5. At least one of the following: (a) dysplasia in one or more cell lines, 
(b) an acquired clonal cytogenetic abnormality or molecular genetic
abnormality present in hematopoietic cells, or (c) persistence of
monocytosis for at least 3 months and no evidence of other causes 
of monocytosis (such as infection, inflammation or malignancy).
CMML from MDS.35 A new group of diseases with both
myelodysplastic and myeloproliferative features was
established, named “myelodysplastic/myeloproliferative
diseases” including CMML, atypical CMML, and juvenile
CMML.  WHO committees chose not to maintain the dis-
tinction between MD and MP CMML, but to divide
CMML into two prognostic categories based on blast
number: CMML-1 (blasts < 5% in blood and < 10% in
BM) and CMML-2 (blasts 5-19% in blood and/or 10-19%
in BM). A diagnostic sub-category of “CMML with
eosinophilia” was recommended in cases where peripher-
al eosinophil counts resulted over 1.5x109/L.
The WHO classification was reviewed in 20081 and
“myelodysplastic/myeloproliferative diseases” were
renamed “myelodysplastic/myeloproliferative neo-
plasms”. A new subgroup, “myeloid and lymphoid neo-
plasm with eosinophilia and abnormalities of PDGRFA,
PDGRFB and FGFR1”, was added. “CMML with
eosinophilia” harboring PDGRFA or PDGRFB rearrange-
ment was included in this new entity.
Recommendations
Diagnostic criteria for CMML are clearly set out in the
WHO 2008 classification and their use is recommended
(Table 2). We suggest that the distinction of CMML into
MP- and MD-variants should be maintained in the diag-
nostic workup, since it retains importance due to the
different therapeutic options that this may involve. For
the time being, although arbitrary, a white blood cell
count of 13x109/L is considered an appropriate cut-off
point for this distinction.
Prognosis and risk classification
In the past, patients with CMML were usually assessed
for risk using scoring systems developed for MDS.36 In
2002, a specific prognostic scoring system was developed
at the University of Texas MD Anderson Cancer Center
(MDACC).37 This study identified a hemoglobin level (<12
vs. ≥12 g/dL), absolute number of lymphocytes (>2.5 vs.
≤2.5x109/L), the presence of immature myeloid cells (IMC)
in the peripheral blood and marrow blast percentage (≥10
vs. <10%) as the variables independently associated to
prognosis that could identify four subgroups of patients
(low, intermediate-1, intermediate-2, and high risk, with
median survival times of 26, 14, 9, and 5 months, respec-
tively) showing significantly different life expectations
(MDAPS). The association of higher lymphocyte counts
with shorter survival has been confirmed by the MDS
Düsseldorf Registry.38 A few years later, a slight modifica-
tion of the MDAPS was proposed (MDAPS M1) replacing
BM blasts with LDH, which allowed a slightly better strat-
ification in four risk groups to be obtained in comparison
to the original MDAPS.39
The presence of cytogenetic aberrations has been asso-
ciated to shorter survival in CMML,37 in particular in
patients with high-risk disease.39 A recent multivariate
analysis of 414 CMML patients included in the Spanish
MDS Registry confirmed the independent association of
an abnormal karyotype (reported in 27% of patients) with
poorer overall survival and a higher risk of AML
evolution.40
Independent associations of molecular abnormalities
with prognosis have been recently identified.14 Indeed, the
presence of RAS point mutations appears to be significant-
ly higher in MP-CMML than in MD-CMML (40% vs.
20%).41 The presence of EZH2 implies an unfavorable
prognosis8 while mutation of ASXL1 correlates with evo-
lution to AML and a shorter overall survival.18 The impact
of TET2 mutations remains controversial.9,42 No impact of
SRSF2 mutation on survival was observed.22 However, in
the RUNX1 mutated sub-cohort, SRSF2 Pro95His had a
favorable impact on overall survival.22 Most important, a
recently concluded phase II trial in which 39 CMML
patients were treated with decitabine suggested that
lower CJUN and CMYB gene expression levels were inde-
pendently associated with an improved overall outcome
and survival.43 However, the value of somatic gene muta-
tions in the prognosis of CMML has not been validated
and no scoring system including such molecular aberra-
tions has been developed.
Recommendations
Because life expectancy is so heterogeneous in
CMML, risk assessment is highly recommended for
clinical decision making in individual patients.
The CMML-1 and CMML-2 WHO classification is
recommended for prognostic implications but it should
not be considered sufficient on its own to discriminate
between low- and high-risk patients. Additional clinical
criteria should be taken into account to decide the tim-
ing and modalities of therapeutic interventions.
At present, there is no universally used validated
CMML-specific risk classification system. The use of
CMML specific risk-oriented systems (i.e. MDAPS,
MDAPS-M1, Düsseldorf or Spanish Registry scores) for
individual patient risk assessment is recommended, in
particular for patients who are candidates for allogeneic
HSCT or enrolled in clinical trials.
Determinants of therapeutic intervention
Although criteria for starting therapy in CMML have
not yet been fully established, the panel reasoned that
clinical relevance should be considered when deciding the
criteria for starting therapy. Thus empirical values were
selected for the severity of anemia, thrombocytopenia,
percentage of blasts and immature myeloid cells. The
panel agreed on the following recommendations.
Recommendations
Therapy should be started when the disease is sympto-
matic or progressive, and, in particular, when one of
these events occurs: a) severe anemia (Hb less than 10
g/dL); b) percentage of blasts in peripheral blood >5%
(including myeloblasts, monoblasts and promonocytes;)
c) platelet count ≤ 50x109/L; d) WBC count ≥ 30x109/L; e)
immature granulocytes ≥ 10% in peripheral blood; f)
extramedullary manifestations of the disease, such as
cutaneous or lymphnodal; g) symptomatic splenomegaly.
Response criteria and definition of resistance 
In 1996, Wattel et al. proposed five grades of response
(clinical remission, good response, minor response, pro-
gression and stable disease) based on blood count, bone
marrow aspirate and biopsy, and karyotype. However,
these criteria were not used thereafter.44 Stressing the need
for response criteria that are specific for CMML, the panel
concluded that, at present, either the IWG 2006 response
criteria for MDS or the IWG response criteria for myelofi-
brosis are appropriate for CMML in the myelodysplastic
and myeloproliferative variants, respectively45,46 (Tables 3
F. Onida et al.
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and 4). There is no universally applied standardized defi-
nition of resistance/intolerance to first-line therapy (either
hydroxyurea or 5-azacytidine) in CMML. 
Recommendations
Response to treatment should be assessed according
to the MD- and MP-disease classification at the time of
treatment. For patients with MD-CMML, the IWG 2006
criteria for MDS (Table 3) should be applied. For
patients with MP-CMML, the same set of IWG criteria
of response used for primary myelofibrosis should be
applied (IWG 2009 - Table 4). In both variants of the
disease, the distinction of patients according to the
WHO classification (CMML-1 vs. CMML-2) does not
imply modifications of response criteria.
In MD-CMML, the absence of hematologic improve-
ment after at least six cycles of 5-azacytidine and with-
out progression of the disease should be defined as
resistance. In MP-CMML, the same criteria used for
defining resistance to hydroxyurea in myelofibrosis may
be used47 (Table 5).
Monitoring patients not candidates for treatment
The frequency of clinical and laboratory monitoring in
patients who are not candidates for treatment should be
initially set according to the individual disease characteris-
tics and then adjusted depending on the natural clinical
course.
Recommendations
Patients with MD-CMML who are not candidates for
treatment should be monitored with a full blood count
one month after diagnosis to assess the hematologic sta-
bility. These patients should then be monitored by  full
blood count and clinical examination every three
months. 
Patients with MP-CMML at diagnosis or evolving
from an MD-CMML and not candidates for treatment,
should be monitored monthly by full blood count for
the first three months from diagnosis to exclude a rapid
rise in WBC count or significant changes in other hema-
tologic parameters, then by complete whole blood
count and clinical examination every three months.
Clinical examination should aim to evaluate spleen size,
and  the appearance of lymphoadenomegalies or extra-
hematologic involvement (e.g. skin).  
In cases of disease evolution from MD- to MP-
CMML, as well as in cases of a significant increase in
WBC count or a considerable spleen size enlargement in
patients with a previously stable MP-CMML, hemato-
logic and cytogenetic re-evaluation is recommended.
Molecular evaluation should be considered, storing
marrow cell DNA for further studies. 
In patients not candidates for stem cell transplanta-
tion or any other possible experimental treatment, BM
examination for blast count and cytogenetics should be
performed once a year and in cases of relevant hemato-
logic changes.
First-line therapy
Management of CMML is usually focused on supportive
care and cytoreductive therapy, depending on the charac-
teristics of individual patient’s disease (MD- vs. MP-
CMML). Wattel et al. compared 1,000 mg/day of oral
hydroxyurea (HU) to 150 mg/week of oral etoposide in
105 patients.44 After a median follow up of 11 months,
60% of patients in the HU arm responded compared with
36% in the etoposide arm. Median overall survival (OS)
was statistically superior in the UH arm leading to the trial
ending early. 
Two randomized studies established the efficacy and
safety of hypomethylating agents (5-azacitidine and
Recommendations for CMML
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Table 3. Modified IWG response criteria in myelodysplasia.45
Category Response criteria (responses must last at least 4 weeks)
Complete remission Bone marrow: ≤ 5% myeloblasts with normal maturation of all cell lines
Persistent dysplasia will be noted
Peripheral blood: Hb ≥ 11 g/dL,  platelets ≥ 100×109/L, neutrophils ≥ 1.0×109/L, blasts 0%
Partial remission All CR criteria if abnormal before treatment except: 
bone marrow blasts decreased by ≥ 50% over pre-treatment but still > 5% 
cellularity and morphology not relevant 
Marrow CR Bone marrow: ≤ 5% myeloblasts and decrease by ≥ 50% over pre-treatment
Peripheral blood: if HI responses, they will be noted in addition to marrow CR
Stable disease Failure to achieve at least PR, but no evidence of progression for > 8 weeks 
Failure Death during treatment or disease progression characterized by worsening of cytopenias, increase in percentage of bone 
marrow blasts, or progression to a more advanced MDS FAB subtype than pre-treatment 
Relapse after CR or PR At least 1 of the following: return to pre-treatment bone marrow blast percentage; decrement of ≥ 50% from maximum 
remission/response levels in granulocytes or platelets; reduction in Hb concentration by ≥ 1.5 g/dL or transfusion dependence
Cytogenetic response Complete: disappearance of the chromosomal abnormality without appearance of new ones 
Partial: at least 50% reduction of the chromosomal abnormality
Disease progression For patients with: 
less than 5% blasts: ≥ 50% increase in blasts to > 5% blasts 
5%-10% blasts: ≥ 50% increase to > 10% blasts 
10%-20% blasts: ≥ 50% increase to > 20% blasts 
20%-30% blasts: ≥ 50% increase to > 30% blasts 
Any of the following: 
at least 50% decrement from maximum remission/response in granulocytes or platelets; Reduction in Hb by ≥ 2 g/dL;
transfusion dependence 
decitabine) in a total of 361 patients with MDS.48,49
However, only 14 patients with CMML were enrolled in
each of these studies. Although the responses for CMML
patients were not reported separately in the trials, it was
reported that there were no significant differences in
response rates among patients with refractory anemia as
compared to CMML. Only one out of the 7 CMML
patients randomized to the decitabine arm had a
response. 5-azacitidine and decitabine have been
approved by the US FDA for the treatment of CMML.
More restricted approval was given by the EMA who
indicated 5-azacitidine for the treatment of CMML-2 in
absence of myeloproliferative aspects (<13x109/L WBC)
therefore allowing a treatment indication only in 10-20%
of patients. Recently, Costa et al. retrospectively reviewed
38 CMML patients treated with two different schedules
of 5-azacytidine and reported a 39% overall response rate
(ORR) and a significantly improved survival in responders
versus non-responders.50 In a retrospective study, clinical
data of 31 patients with CMML consecutively treated
with 5-azacitidine were collected.51 5-azacitidine was
administered at 75 mg/m2 or 50 mg/m2 daily for 7 days, or
at 100 mg daily for 5 or 7 days, every 4 weeks. Overall,
51% of the patients responded to the drug, with a high
rate of complete remissions (CR), while hematologic
improvement (HI) was obtained in 2 patients. The disease
remained stable in 7 patients (SD, 23%) while 8 patients
(26%) were resistant to the drug. Patients responding to
5-azacitidine had a better survival than those with SD or
progression. The use of 5-azacytidine in MP-CMML is
debated because at low doses the drug primarily acts as a
demethylating agent, with minimal cytotoxicity that is
unable to control high proliferation rates.52 In contrast to
this observation, a recent study on a small group of 10
CMML patients treated with 5-azacytidine reported an
ORR of 60%. Response was increased in proliferative
CMML, with good control of leukocytosis and achieve-
ment of transfusion independence in 66% of the
patients.53
Phase II studies using decitabine showed ORRs ranging
from 38% to 70%.54,55 A recent trial of decitabine 20
mg/m2/day for 5 days carried out on a median of 10 cycles
in CMML patients with advanced myeloproliferative or
myelodysplastic features indicated an ORR of 38%  and
suggested that a lower CJUN and CMYB expression could
be predictive of response.43
Intensive chemotherapy with intermediate doses of
Ara-C and topotecan was investigated in a phase II trial in
CMML, obtaining a CR rate of 44%, with a median remis-
sion duration of 33 weeks and a median survival of 41
weeks.56 Therapy with topotecan as single agent induced
CR in 28% of CMML patients, with a median survival
time of 10.5 months, and a median CR duration of 7.5
months.57 In a more recent trial in 90 patients with MDS
and CMML treated with oral topotecan following 2 differ-
ent schedules, the response rate in CMML patients was
F. Onida et al.
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Table 4. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis.46
1. Complete remission (CR) i. Complete resolution of disease-related symptoms and signs including palpable hepatosplenomegaly. 
ii. Peripheral blood count remission defined as hemoglobin level at least 110 g/L, platelet count at least 100×109/L, and
absolute neutrophil count at least 1.0×109/L. In addition, all 3 blood counts should be no higher than the upper normal
limit. 
iii. Normal leukocyte differential including disappearance of nucleated red blood cells, blasts, and immature myeloid 
cells in the peripheral smear, in the absence of splenectomy.
iv. Bone marrow histological remission defined as the presence of age-adjusted normocellularity, no more than 5% 
myeloblasts, and an osteomyelofibrosis grade no higher than 1.
2. Partial remission (PR) Requires all of the above criteria for CR except the requirement for bone marrow histological remission. However, a repeat
bone marrow biopsy is required in the assessment of PR and may or may not show favorable changes that do not however 
fulfill criteria for CR. 
3. Clinical improvement (CI) Requires one of the following in the absence of both disease progression (as outlined below) and CR/PR assignment 
(CI response is validated only if it lasts for no fewer than 8 weeks) 
i. A minimum 20-g/L increase in hemoglobin level or becoming transfusion independent (applicable only for patients 
with baseline hemoglobin level of less than 100 g/L). 
ii. Either a minimum 50% reduction in palpable splenomegaly of a spleen that is at least 10 cm at baseline or a spleen 
that is palpable at more than 5 cm at baseline becomes not palpable. 
iii. A minimum 100% increase in platelet count and an absolute platelet count of at least 50 000×109/L (applicable only 
for patients with baseline platelet count below 50×109/L). 
iv. A minimum 100% increase in ANC and an ANC of at least 0.5×109/L (applicable only for patients with baseline absolute
neutrophil count below 1×109/L). 
4. Progressive disease (PD) Requires one of the following: 
i. Progressive splenomegaly that is defined by the appearance of a previously absent splenomegaly that is palpable 
at greater than 5 cm below the left costal margin or a minimum 100% increase in palpable distance for baseline
splenomegaly of 5-10 cm or a minimum 50% increase in palpable distance for baseline splenomegaly of greater than 10 cm. 
ii. Leukemic transformation confirmed by a bone marrow blast count of at least 20%. 
iii. An increase in peripheral blood blast percentage of at least 20% that lasts for at least 8 weeks. 
5. Stable disease (SD) None of the above. 
6. Relapse Loss of CR, PR, or CI. In other words, a patient with CR or PR is considered to have undergone relapse when he or she 
no longer fulfills the criteria for even CI. However, changes from either CR to PR or CR/PR to CI should be documented
and reported.
50%, but no CR was reached.58
As CMML, especially in its proliferative variant, has the
highest frequency of N- and K-RAS mutations among
hematologic malignancies, farnesyl transferase inhibitors
were considered potential effective drugs. Tipifarnib and
lonafarnib were the most closely studied: unfortunately,
both drugs, as single agents, were effective in only a few
patients, resulting in limited disease control and leading to
sporadic CR.59,60
In a pilot study, bendamustine was utilized in 15 pre-
treated elderly patients with AML or high-risk MDS.61
Recommendations
Patients who start therapy later than three months
from the diagnosis should have a pre-treatment re-eval-
uation, including BM aspiration, BM biopsy, and cyto-
genetic analysis. HLA typing is recommended for
patients aged under 65 years. Serum erythropoietin
should be determined in all patients with severe anemia
(Hb ≤ 10 g/dL). 
The treatment strategy should be decided first accord-
ing to the disease hematologic phenotype, in particular
whether it is an MP or MD phenotype, and to the num-
ber of blasts in BM. 
Patients with MD-CMML and less than 10% blasts in
BM should be managed with supportive therapy aimed
at correcting cytopenias. Patients with severe anemia
(Hb ≤ 10g/dL and with serum erythropoietin ≤ 500
mU/dL) should be treated with erythropoietic stimulat-
ing agents. Myeloid growth factors may be considered
only for patients with febrile severe neutropenia. 
In patients with MD-CMML with high number of
blasts (≥10% in BM, ≥5% in the blood), the supportive
therapy should be integrated with the use of
hypomethylating agents (5-azacytidine or decitabine).
In selected patients, allo-SCT may be offered within
clinical trials.
Patients with MP-CMML with a low number of blasts
should be treated with cytoreductive therapy.
Hydroxyurea is the drug of choice to control prolifera-
tive myelomonocytic cells and to reduce organomegaly. 
Patients with MP-CMML and a high number of blasts
should receive blastolytic therapy with polychemother-
apy followed, when possible, by allo-SCT.
If allo-SCT is not a possible option, patients should be
informed that, although not curative, chemotherapy is
recommended to maintain Quality of Life.
Second-line treatment
In the absence of any scientific evidence that could
address the decision on second-line therapy in patients
refractory or intolerant to first-line treatment, the panel
approved the following recommendations.
Recommendations
Patients with MD-CMML with a high number of
blasts, resistant or intolerant to 5-azacitidine, and not
eligible for transplant, should be treated with support-
ive therapy and enrolled in experimental therapeutic
studies.
In patients with MP-CMML and resistant or intoler-
ant to hydroxyurea (Table 5) without blasts (<10%),
cytolytic therapy should be given to control the disease
and avoid a rapid increase in WBC count. VP16, low-
dose ARA-C, thioguanine as single agents are reported
to be efficacious. Hypomethylating agents should be
used in the context of clinical trials. Patients with MP-
CMML with a high blast count resistant to conventional
blastolytic therapies should be treated with new and
experimental therapies.  Topoisomerase I inhibitors, far-
nesyl-transferase inhibitors or other drugs like ben-
damustine seem to have little effect as single agents.
Hematopoietic stem cell transplantation  
Allo-SCT is the only strategy that may lead to cure in
patients with CMML. However, due to the advanced age
of the vast majority of patients, this treatment option is
rarely feasible. Recently,62 a literature search was per-
formed and data from adult CMML patients undergoing
allo-SCT were reviewed. In all, 197 patients from eight
studies63-70 met the final inclusion criteria. All studies were
retrospective, 6 out of 8 (71%) being single institution
experiences. The overall results of allogeneic SCT follow-
ing myeloablative conditioning in CMML patients were
disappointing, indicating a manifest excess mortality. The
overall survival (OS) at 2-10 years ranged from 18% to
75% for all studies: relapse-free survival (RFS) ranged from
18% to 67% . Reduced intensity conditioning (RIC) trans-
plant improved non-relapse mortality, OS and RFS with-
out increasing the relapse rate. 
Recommendations
The panel agreed that allo-SCT should be considered
a therapeutic option in CMML for fit patients aged
under 60 years with high-risk CMML requiring treat-
ment. Its use should be considered experimental under
a controlled strategy that investigates new pre-trans-
plant therapies and transplant protocols. In MP-CMML
and a high number of blasts, allo-SCT should be preced-
ed by polychemotherapy, whereas in MD-CMML, 5-
azacytidine may be considered before enrolling patients
in a program of allo-SCT.
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Table 5. Definition of resistance/intolerance to hydroxyurea.47
1. Failure to: (i) reduce massive (organ extending by more than 10 cm from the costal margin), or progressive (organ increasing by more than 3 cm 
in the last 3 months) splenomegaly, by more than 50% as measured by palpation, OR, (ii) completely relieve symptoms of splenomegaly after 3 months
of at least 2 g/day of hydroxyurea
2. Uncontrolled myeloproliferation, i.e. platelet count >400×109/L and white blood cell count >10×109/L after 3 months of at least 2 g/day 
of hydroxyurea, OR
3. Absolute neutrophil count <1·0×109/L, or platelet count <50×109/L at the lowest dose of hydroxyurea required to achieve a complete or major
clinico-hematologic response, OR.
4. Presence of leg ulcers or other unacceptable hydroxyurea-related non-hematologic toxicities, such as mucocutaneous manifestations, 
gastrointestinal symptoms, pneumonitis or fever at any dose of hydroxyurea
Discussion
Few recommendations in this work were grounded on
strong scientific evidence, thus most of them reflect the
uncertainty surrounding many issues in CMML. A critical
issue in the disease assessment derives from recent com-
prehensive studies of somatic gene mutations. In these
analyses, more than 80% of patients were found to have
gene aberrations, and it has been hypothesized that such
mutations, especially in the SRSF2, TET2, ASXL genes,
represent disease-associated diagnostic markers. The
panel concluded that these aberrancies must be validated
before entering clinical practice. The hope is that integrat-
ing genetic lesions with traditional prognostic markers
could lead to a better definition of risk classes, improving
the indications for different therapeutic strategies.
The second issue is reflected in the recently revised WHO
classification of CMML, which specifies hematologic, mor-
phological and molecular parameters distinguishing two
clinical CMML types on the basis of the number of blasts.
However, the experts in this work considered that this dis-
tinction is not fully exploitable in therapeutic decision mak-
ing. They believe that the previously reported distinction
between myelodysplastic and myeloproliferative character-
istics retains a clinical relevance in therapeutic decision
making and that a validation of this distinction and correla-
tion with genetic or molecular characteristics of the disease
could improve patients’ stratification for therapy. 
A difficult therapeutic decision is that of advising
patients about allo-SCT. The panel recommended that
allo-SCT should be performed as an experimental proce-
dure. Nevertheless, by significantly reducing toxicities and
extending the allo-SCT option to older patients, approach-
es based on reduced intensity conditioning transplant are
definitely worth investigating in CMML.
Last-minute addendum
Since submission of the paper, a new CMML-specific
prognostic scoring system (CPSS) has been published by
Such et al.71 The most relevant variables for overall survival
and evolution to acute myeloblastic leukemia were FAB
and WHO CMML subtypes, CMML-specific cytogenetic
risk classification, and RBC transfusion dependency. CPSS
was able to segregate patients into four clearly different
risk groups for OS and risk of AML evolution. 
Acknowledgment
Authorship contribution: GB and ST designed the research.
FO, GL, LM, EM, VS, GS and ST formed the panel of experts
who produced recommendations. FO and GB wrote the prelimi-
nary version of the paper. All authors participated in writing sig-
nificant sections of the paper.
Funding
Funding of the project was provided by SIE, SIES, and
GITMO societies. The SIE administered all aspects of the meet-
ings. 
Authorship and Disclosures
Information on authorship, contributions, and financial & other
disclosures was provided by the authors and is available with the
online version of this article at www.haematologica.org.
F. Onida et al.
1350 haematologica | 2013; 98(9)
References
1. Swerdlow SH, Campo E, Harris NL, Jaffe
ES, Pileri SA, Stein H, et al. (eds.): WHO
Classification of Tumours of
Haematopoietic and Lymphoid Tissues.
IARC: Lyon, 2008
2. Parikh SA, Tefferi A. Chronic myelomono-
cytic leukemia: 2012 update on diagnosis,
risk stratification, and management. Am J
Hematol. 2012;87(6):610-9.
3. Beran M. Chronic myelomonocytic
leukemia. Cancer Treat Res. 2008;142:107-
32.
4. Williams PL, Webb C. The Delphi tech-
nique: a methodological discussion. J Adv
Nurs. 1994;19(1):180-6.
5. Delbecq AL, van de Ven AH, Gustafson
DH. Group Techniques for Program
Planning: A guide to nominal group and
Delphi processes. Scott, Foresman and Co.
Glenview, IL, USA 1975.
6. Bacher U, Haferlach T, Kern W,
Hiddemann W, Schnittger S, Schoch C.
Conventional cytogenetics of myeloprolif-
erative diseases other than CML contribute
valid information. Ann Hematol. 2005;84
(4):250-7. 
7. Haase D, Germing U, Schanz J, Pfeilstöcker
M, Nösslinger T, Hildebrandt B, et al. New
insights into the prognostic impact of the
karyotype in MDS and correlation with
subtypes: Evidence from a core dataset of
2124 patients. Blood. 2007;110(13):4385-
95.
8. Grossmann V, Kohlmann A, Eder C,
Haferlach C, Kern W, Cross NC, et al.
Molecular profiling of chronic myelomono-
cytic leukemia reveals diverse mutations in
>80% of patients with TET2 and EZH2
being of high prognostic relevance.
Leukemia. 2011;25(5):877-9.
9. Kohlmann A, Grossmann V, Klein HU,
Schindela S, Weiss T, Kazak B, et al. Next-
generation sequencing technology reveals a
characteristic pattern of molecular muta-
tions in 72.8% of chronic myelomonocytic
leukemia by detecting frequent alterations
in TET2, CBL, RAS, and RUNX1. J Clin
Oncol. 2010;28(24):3858-65.
10. Jankowska AM, Makishima H, Tiu RV,
Szpurka H, Huang Y, Traina F, et al.
Mutational spectrum analysis of chronic
myelomonocytic leukemia includes genes
associated with epigenetic regulation:
UTX, EZH2, and DNMT3A. Blood. 2011;
118(14):3932-41.
11. Asou N. The role of a Runt domain tran-
scription factor AML1/RUNX1 in leukemo-
genesis and its clinical implications. Crit
Rev Oncol Hematol. 2003;45(12):129-50.
12. Kuo MC, Liang DC, Huang CF, Shih YS,
Wu JH, Lin TL, et al. RUNX1 mutations are
frequent in chronic myelomonocytic
leukemia and mutations at the C-terminal
region might predict acute myeloid
leukemia transformation. Leukemia. 2009;
23(8):1426-31.
13. Ward PS, Patel J, Wise DR, Abdel-Wahab
O, Bennett BD, Coller HA, et al. The com-
mon feature of leukemia-associated IDH1
and IDH2 mutations is a neomorphic
enzyme activity converting alpha-ketoglu-
tarate to 2-hydroxyglutarate. Cancer Cell.
2010;17(3):225-34.
14. Gelsi-Boyer V, Trouplin V, Adélaïde J,
Aceto N, Remy V, Pinson S, et al. Genome
profiling of chronic myelomonocytic
leukemia: Frequent alterations of RAS and
RUNX1 genes. BMC Cancer. 2008;8:299.
15. Ricci C, Fermo E, Corti S, Molteni M,
Faricciotti A, Cortelezzi A, et al. RAS muta-
tions contribute to evolution of chronic
myelomonocytic leukemia to the prolifera-
tive variant. Clin Cancer Res. 2010;16(18):
2246-56.
16. Pich A, Riera L, Sismondi F, Godio L,
Davico Bonino L, Marmont F, et al.
JAK2V617F activating mutation is associat-
ed with the myeloproliferative type of
chronic myelomonocytic leukaemia. J Clin
Pathol. 2009;62(9):798-801.
17. Grand FH, Hidalgo-Curtis CE, Ernst T, Zoi
K, Zoi C, McGuire C, et al. Frequent CBL
mutations associated with 11q acquired
uniparental disomy in myeloproliferative
neoplasms. Blood. 2009;113(24):6182-92.
18. Gelsi-Boyer V, Trouplin V, Adélaïde J,
Bonansea J, Cervera N, Carbuccia N, et al.
Mutations of polycomb-associated gene
ASXL1 in myelodysplastic syndromes and
chronic myelomonocytic leukaemia. Br J
Haematol. 2009;145(6):788-800.
19. Abdel-Wahab O, Pardanani A, Patel J,
Wadleigh M, Lasho T, Heguy A, et al.
Concomitant analysis of EZH2 and ASXL1
mutations in myelofibrosis, chronic
myelomonocytic leukemia and blast-phase
myeloproliferative neoplasms. Leukemia
2011;25(7):1200-2.
20. Tefferi A, Lim KH, Abdel-Wahab O, Lasho
TL, Patel J, Patnaik MM, et al. Detection of
mutant TET2 in myeloid malignancies
other than myeloproliferative neoplasms:
CMML, MDS, MDS/MPN and AML.
Leukemia. 2009;23(7):1343-5.
21. Jankowska AM, Szpurka H, Tiu RV,
Makishima H, Afable M, Huh J, et al. Loss




22. Meggendorfer M, Roller A, Haferlach T,
Eder C, Dicker F, Grossmann V, et al. SRSF2
mutations in 275 cases with chronic
myelomonocytic leukemia (CMML).
Blood. 2012;120(15):3080-8.
23. Rashidi HH, Xu X, Wang HY, Shafi NQ,
Rameshkumar K, Messer K, et al. Utility of
peripheral blood flow cytometry in differ-
entiating low grade versus high grade
myelodysplastic syndromes (MDS) and in
the evaluation of cytopenias. Int J Clin Exp
Pathol. 2012;5(3):224-30. 
24. Bellos F, Alpermann T, Gouberman E,
Haferlach C, Schnittger S, Haferlach T, et
al. Evaluation of flow cytometric assess-
ment of myeloid nuclear differentiation
antigen expression as a diagnostic marker
for myelodysplastic syndromes in a series
of 269 patients. Cytometry B Clin Cytom.
Cytometry B Clin Cytom. 2012;82
(15):295-304. 
25. Rollins-Raval MA, Roth CG. The value of
immunohistochemistry for CD14, CD123,
CD33, myeloperoxidase and CD68R in the
diagnosis of acute and chronic myelomono-
cytic leukaemias. Histopathology. 2012;60
(6):933-42. 
26. Bennett JM, Catovsky D, Daniel MT,
Flandrin G, Galton DA, Gralnick HR, et al.
Proposals for the classification of the
myelodysplastic syndromes. Br J Haematol.
1982;51(2):189-99.
27. Bennett JM, Catovsky D, Daniel MT,
Flandrin G, Galton DA, Gralnick H, et al.
The chronic myeloid leukaemias: guide-
lines for distinguishing chronic granulocyt-
ic, atypical chronic myeloid, and chronic
myelomonocytic leukaemia. Proposals by
the French–American–British Cooperative
Leukaemia Group. Br J Haematol. 1994;87
(4):746-54.
28. Germing U, Gattermann N, Minning H,
Heyll A, Aul C. Problems in the classifica-
tion of LMMC--dysplastic versus prolifera-
tive type. Leuk Res. 1998;22(10):871-8.
29. Voglová J, Chrobák L, Neuwirtová R,
Malasková V, Straka L. Myelodysplastic
and myeloproliferative type of chronic
myelomonocytic leukemia - distinct sub-
groups or two stages of the same disease?
Leuk Res. 2001;25(6):493-9.
30. Nösslinger T, Reisner R, Grüner H, Tüchler
H, Nowotny H, Pittermann E, et al.
Dysplastic versus proliferative LMMC - a
retrospective analysis of 91 patients from a
single institution. Leuk Res. 2001;25
(9):741-7.
31. Onida F, Kantarjian H, Ball G, Estey E,
Keating MJ, Glassman A, et al. The dysplas-
tic versus proliferative classification dilem-
ma of chronic myelomonocytic leukemia: a
retrospective single institution analysis of
273 patients. Blood. 2001, 98;11(1 Suppl):
622A-623A.
32. Cervera J, Sanz GF, Vallespi T, del Cañizo
MC, Irriguible D, Löpez F, et al. Does WBC
count really define two different subtypes
of chronic myelomonocytic leukemia
(LMMC)? Analysis of a series of 119
patients. Leuk Res. 1997;21(4):S7.
33. González-Medina I, Bueno J, Torre -
quebrada A, López A, Vallespí T, Massagué
I, et al. Two groups of chronic myelomono-
cytic leukaemia: myelodysplastic and
myeloproliferative. Prognostic implications
in a series of a single center. Leuk Res.
2002;26(9):821-4.
34. Breccia M, Cannella L, Frustaci A,
Stefanizzi C, D'Elia GM, Alimena G, et al.
Chronic myelomonocytic leukemia with
antecedent refractory anemia with excess
blasts: further evidence for the arbitrary
nature of current classification systems.
Leuk Lymphoma. 2008;49(7):1292-6.
35. Jaffe E, Harris NL, Stein HS, Vardiman JW
(eds.). Pathology and genetics of tumours of
haematopoietic and lymphoid tissue.
World Health Organization classification of
tumours. Lyon: IARC Press, 2001,pp. 35-38.
36. Greenberg P, Cox C, LeBeau MM, Fenaux P,
Morel P, Sanz G, et al. International scoring
system for evaluating prognosis in
myelodysplastic syndromes. Blood.
1997;89(6):2079-88.
37. Onida F, Kantarjian HM, Smith TL, Ball G,
Keating MJ, Estey EH, et al. Prognostic fac-
tors and scoring systems in chronic
myelomonocytic leukemia: a retrospective
analysis of 213 patients. Blood. 2002;99
(3):840-9.
38. Germing U, Strupp C, Alvado M,
Gattermann N. New Prognostic parameters
for myelomonocytic leukemia. Blood.
2002;100(2):731-3.
39. Beran M, Wen S, Shen Y, Onida F, Jelinek J,
Cortes J, et al. Prognostic factors and risk
assessment in chronic myelomonocytic
leukemia: validation study of the M.D.
Anderson Prognostic Scoring System. Leuk
Lymphoma. 2007;48(6):1150-60.
40. Such E, Cervera J, Costa D, Solé F, Vallespí
T, Luño E, et al. Cytogenetic risk stratifica-
tion in chronic myelomonocytic leukemia.
Haematologica. 2011;96(3):375-83.
41. Onida F, Gatto S, Scappini B, Ricci C, Ball
G, Cortes J, et al. Significance of Ras point
mutations for prognosis and response to
treatment in chronic myelomonocytic
leukemia: analysis of 112 patients. Proc Am
Soc Clin Oncol. 2002;21:263a(1048).
42. Kosmider O, Gelsi-Boyer V, Ciudad M,
Racoeur C, Jooste V, Vey N, et al. TET2
gene mutation is a frequent and adverse
event in chronic myelomonocytic leu -
kemia. Haematologica. 2009;94(12): 1676-
81. 
43. Braun T, Itzykson R, Renneville A, de
Renzis B, Dreyfus F, Laribi K, et al.
Molecular predictors of response to
decitabine in advanced chronic myelo -
monocytic leukemia: a phase 2 trial. Blood.
2011;118(14):3824-31.
44. Wattel E, Guerci A, Hecquet B, Econo -
mopoulos T, Copplestone A, Mahé B, et al.
A randomized trial of hydroxyurea versus
VP16 in adult chronic myelomonocytic
leukemia. Groupe Francais des Myelo -
dysplasies and European CMML Group.
Blood. 1996;88(17):2480-7.
45. Cheson BD, Greenberg PL, Bennett JM,
Lowenberg B, Wijermans PW, Nimer SD, et
al. Clinical application and proposal for
modification of the International Working
Group (IWG) response criteria in
myelodysplasia. Blood. 2006;108(2):419-25. 
46. Tefferi A, Barosi G, Mesa RA, Cervantes F,
Deeg HJ, Reilly JT, et al. International
Working Group (IWG) consensus criteria
for treatment response in myelofibrosis
with myeloid metaplasia, for the IWG for
Myelofibrosis Research and Treatment
(IWG-MRT). Blood. 2006;108(5):1497-503.
47. Barosi G, Birgegard G, Finazzi G,
Griesshammer M, Harrison C, Hasselbalch
H, et al. A unified definition of clinical
resistance and intolerance to hydroxycar-
bamide in polycythaemia vera and primary
myelofibrosis: results of a European
LeukemiaNet (ELN) consensus process. Br J
Haematol. 2010;148(6):961-3.
48. Silverman LR, Demakos EP, Peterson BL,
Kornblith AB, Holland JC, Odchimar-
Reissig R, et al. Randomized controlled trial
of azacitidine inpatients with the
myelodysplastic syndrome: a study of the
cancer and leukemia group B. J Clin Oncol.
2002;20(10):2429-40.
49. Kantarjian H, Issa JP, Rosenfeld CS, Bennett
JM, Albitar M, DiPersio J, et al. Decitabine
improves patient outcomes in myelodys-
plastic syndromes: results of a phase III ran-
domized study. Cancer. 2006;106(8):1794-
803.
50. Costa R, Abdulhaq H, Haq B, Shadduck
RK, Latsko J, Zenati M, et al. Activity of
azacitidine in chronic myelomonocytic
leukemia. Cancer. 2011;117(12):2690-6.
51. Fianchi L, Criscuolo M, Breccia M, Maurillo
L, Salvi F, Musto P, et al. High rate of remis-
sions in chronic myelomonocytic leukemia
treated with 5-azacytidine: results of an
Italian retrospective study. Leuk
Lymphoma. 2013;54(3):658-61.
52. Tsai HC, Li H, Van Neste L, Cai Y, Robert
C, Rassool FV, et al. Transient low doses of
DNA-demethylating agents exert durable
antitumor effects on hematological and
epithelial tumor cells. Cancer Cell. 2012;21
(3):430-46.
53. Thorpe M, Montalvão A, Pierdomenico F,
Moita F, Almeida A. Treatment of chronic
myelomonocytic leukemia with 5-
Azacitidine: A case series and literature
review. Leuk Res. 2012;36 (8):1071-3. 
54. Aribi A, Borthakur G, Ravandi F, Shan J,
Davisson J, Cortes J, et al. Activity of
decitabine, a hypomethylating agent, in
chronic myelomonocytic leukemia. Cancer.
2007;109(4):713-7.
55. Wijermans PW, Rüter B, Baer MR, Slack JL,
Saba HI, Lübbert M. Efficacy of decitabine
in the treatment of patients with chronic
myelomonocytic leukemia (CMML). Leuk
Res. 2008;32(4):587-91.
56. Beran M, Estey E, O'Brien S, Cortes J,
Koller CA, Giles FJ, et al. Topotecan and
cytarabine is an active combination regi-
men in myelodysplastic syndromes and
chronic myelomonocytic leukemia. J Clin
Oncol. 1999;17(9):2819-30.
57. Beran M, Estey E, O'Brien SM, Giles FJ,
Koller CA, Kornblau S, et al. Results of
topotecan single-agent therapy in patients
with myelodysplastic syndromes and
chronic myelomonocytic leukemia. Leuk
Lymphoma. 1998;31(5-6):521-31.
58. Grinblatt DL, Yu D, Hars V, Vardiman JW,
Powell BL, Nattam S, et al. Treatment of
myelodysplastic syndrome with 2 sched-
ules and doses of oral topotecan: a random-
ized phase 2 trial by the Cancer and
Leukemia Group B (CALGB 19803).
Cancer. 2009;115(1):84-93.
59. Fenaux P, Raza A, Mufti GJ, Aul C,
Germing U, Kantarjian H, et al.  A multi-
center phase 2 study of the farnesyltrans-
ferase inhibitor tipifarnib in intermediate-
to high-risk myelodysplastic syndrome.
Blood. 2007;109(10):4158-63. 
60. Feldman EJ, Cortes J, DeAngelo DJ,
Holyoake T, Simonsson B, O'Brien SG, et
Recommendations for CMML
haematologica | 2013; 98(9) 1351
al. On the use of lonafarnib in myelodys-
plastic syndrome and chronic myelomono-
cytic leukemia. Leukemia. 2008;22(9):
1707-11. 
61. Strupp C, Knipp S, Hartmann J,
Gattermann N, Haas R, Germing U. A pilot
study of bendamustine in elderly patients
with high-risk MDS and AML. Leuk
Lymphoma. 2007;48(6):1161-6.
62. Cheng H, Kirtani VG, Gergis U. Current
status of allogeneic HST for chronic
myelomonocytic leukemia. Bone Marrow
Transplant. 2012;47(4):535-41. 
63. Elliott MA, Tefferi A, Hogan WJ, Letendre
L, Gastineau DA, Ansell SM, et al.
Allogeneic stem cell transplantation and
donor lymphocyte infusions for chronic
myelomonocytic leukemia. Bone Marrow
Transplant. 2006;37(11):1003-8.
64. Kerbauy DM, Chyou F, Gooley T, Sorror
ML, Scott B, Pagel JM, et al.  Allogeneic
hematopoietic cell transplantation for
chronic myelomonocytic leukemia. Biol
Blood Marrow Transplant. 2005;11(9):713-
20.
65. Krishnamurthy P, Lim ZY, Nagi W, Kenyon
M, Mijovic A, Ireland R, et al. Allogeneic
haematopoietic SCT for chronic
myelomonocytic leukaemia: a single-centre
experience. Bone Marrow Transplant.
2010;45(10):1502-7.
66. Kroger N, Zabelina T, Guardiola P, Runde V,
Sierra J, Van Biezen A, et al. Allogeneic
stem cell transplantation of adult chronic
myelomonocytic leukaemia. A report on
behalf of the Chronic Leukaemia Working
Party of the European Group for Blood and
Marrow Transplantation (EBMT). Br J
Haematol. 2002;118(1):67-73.
67. Laport GG, Sandmaier BM, Storer BE, Scott
BL, Stuart MJ, Lange T, et al. Reduced-
intensity conditioning followed by allo-
geneic hematopoietic cell transplantation
for adult patients with myelodysplastic
syndrome and myeloproliferative disor-
ders. Biol Blood Marrow Transplant.
2008;14(2):246-55.
68. Mittal P, Saliba RM, Giralt SA, Shahjahan
M, Cohen AI, Karandish S,  et al. Allogeneic
transplantation: a therapeutic option for
myelofibrosis, chronic myelomonocytic
leukemia and Philadelphia-negative/BCR-
ABL-negative chronic myelogenous leu -
kemia. Bone Marrow Transplant. 2004;
33(10):1005-9.
69. Ocheni S, Kroger N, Zabelina T, Zander
AR, Bacher U. Outcome of allo-SCT for
chronic myelomonocytic leukemia. Bone
Marrow Transplant. 2009;43(8):659-61.
70. Eissa H, Gooley TA, Sorror ML, Nguyen F,
Scott BL, Doney K,  et al. Allogeneic
hematopoietic cell transplantation for
chronic myelomonocytic leukemia:
relapse-free survival is determined by kary-
otype and comorbidities. Biol Blood
Marrow Transplant. 2010;17(6):908-15. 
71. Such E, Germing U, Malcovati L, Cervera J,
Kuendgen A, Della Porta MG, et al.
Development and validation of a prognos-
tic scoring system for patients with chronic
myelomonocytic leukemia. Blood. 2013;
121(15):3005-15.
F. Onida et al.
1352 haematologica | 2013; 98(9)
